These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 27924398

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Milliner D, Hoppe B, Groothoff J.
    Urolithiasis; 2018 Aug; 46(4):313-323. PubMed ID: 28718073
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.
    Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U.
    Nephrol Dial Transplant; 2021 Jul 23; 36(8):1464-1473. PubMed ID: 32810261
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
    Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H.
    Kidney Int; 2006 Oct 23; 70(7):1305-11. PubMed ID: 16850020
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes.
    Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB.
    J Urol; 2001 Oct 23; 166(4):1487-91. PubMed ID: 11547118
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria.
    Sidhu H, Hoppe B, Hesse A, Tenbrock K, Brömme S, Rietschel E, Peck AB.
    Lancet; 1998 Sep 26; 352(9133):1026-9. PubMed ID: 9759746
    [Abstract] [Full Text] [Related]

  • 13. Urinary oxalate excretion in urolithiasis and nephrocalcinosis.
    Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E.
    Arch Dis Child; 2000 Apr 26; 82(4):322-6. PubMed ID: 10735843
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
    Tavasoli S, Alebouyeh M, Naji M, Shakiba Majd G, Shabani Nashtaei M, Broumandnia N, Basiri A.
    BJU Int; 2020 Jan 26; 125(1):133-143. PubMed ID: 31145528
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.